Pramiracetam sulfate, together with aniracetam are two nootropics of the piracetam
family introduced in 1993 for the treatment of attention and memory disorders resulting from
degenerative or vascular disorders in the elderly. In patients with mild to moderate primary
degenerative dementia, treatment with 75-300 mg/day of pramiracetam reduced depression,anxiety, sleep disturbance, and hostility with no observable adverse reactions. Significant
improvement of performance on measures of memory, especially delayed recall, have been
observed for pramiracetam treated patients with brain injury.
